It’s that time of year again — the first few days of January, otherwise known as the grimmest, greyest and dreariest of ...
It was huge. Its light brown shell stood taller than the tip of my shoe. Its yellowish-green body stretched about an inch ...
BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the ...
Learn more about whether Charles River Laboratories International, Inc. or West Pharmaceutical Services, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' ...
SurvivorNet on MSN
Enhertu significantly cuts recurrence rates for women with high-risk HER2-positive breast cancer — the practice-changing DESTINY-Breast05 trial
DESTINY-Breast05 is a large phase 3 trial in women with HER2-positive early-stage breast cancer who had chemotherapy and ...
Daiichi Sankyo Company ($DSKYF) announced an update on their ongoing clinical study. Daiichi Sankyo and Merck Launch New Lung Cancer Study With ...
Is it written “alongside” or “next to”? “In form” or “in form”? “OK” or “alright”? Beyond or afterlife? It often ...
A dedicated bioimaging function at GSK has shown how integrated microscopy and analytics can deliver quantitative evidence ...
Matsue is a city shaped by water, stories and shadow, where ancient Izumo history, folklore, crafts and daily life quietly ...
The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...
Objectives The use of economic evidence to prioritise vaccines and delivery strategies to optimally use in immunisation systems is becoming a global priority, especially in low- and middle-income ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback